Our News

John Maraganore on the "I Am BIO" Podcast: Destroying COVID's Genome

May 1, 2020

Alnylam Pharmaceuticals

Our CEO John Maraganore recently spoke with Biotechnology Innovation Organization (BIO) CEO and Chairman Jim Greenwood on the "I Am BIO" podcast. John and Jim spoke about RNAi therapeutics as an innovative new class of medicines, Alnylam's pipeline and our development program targeting SARS-CoV-2, the virus causes COVID-19. He discusses why we believe that RNAi presents a potentially novel and powerful therapeutic approach to treating and preventing COVID-19 infection and the origins of our COVID-19 collaboration with our partner Vir Biotechnology.  You can learn more about the latest developments in our COVID-19 program here.

 

Tags

RNAi, Podcasts, Podcast, COVID-19, John Maraganore, RNAi, Executive Team

Related Content See All News ›
RNAi Confronting the World’s Leading Killer with a New Therapeutic Approach
RNAi RNAi Therapeutics, from Possibility to Patients
RNAi R&D Day 2023 Recap: Following the Science to Deliver on the Promise of RNAi Therapeutic ...

Categories

Content Types

See All News ›
Related Content See All News ›
RNAi Confronting the World’s Leading Killer with a New Therapeutic Approach
RNAi RNAi Therapeutics, from Possibility to Patients
RNAi R&D Day 2023 Recap: Following the Science to Deliver on the Promise of RNAi Therapeutic ...
See All News ›

FOLLOW US

Visit our social channels to learn more about the innovative work we are doing at Alnylam.

You are now leaving Alnylam.com

The following content may not be associated with Alnylam Pharmaceuticals.

Links to all outside sites are provided as a reference for our visitors.

Alnylam Pharmaceuticals does not endorse and is not responsible for the content on sites that are not owned and operated by Alnylam Pharmaceuticals.

Proceed to Site